Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Arrhythmias in Heart Failure.

Auricchio¹, Klein

¹Department of Cardiology, University Hospital, Otto-von-Guericke Universität, Leipzigerstrasse 44, D-39120 Magdeburg, Germany. Angelo.Auricchio@Medizin.Uni-Magdeburg.DE

Current Treatment Options in Cardiovascular Medicine

|November 30, 2000

Summary

Antiarrhythmic drugs and implantable cardioverter-defibrillators (ICDs) offer benefits for heart failure patients with arrhythmias. The sickest patients with severely reduced ejection fraction benefit most from ICD therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Doubtful Case of Hæmorrhagic Small-Pox.

Transactions. Epidemiological Society of London·2018

Same author

Severe meningitis simulating a subtentorial affection due to posterior crises, operated by the frontal way and cured.

Revue neurologique·2010

Same author

Supraglottic edema; influenza.

Archives of pediatrics·2010

Same author

Differential diagnosis between myotonic dystrophy and myotonia congenitala.

Annales medico-psychologiques·2010

Same author

The Evolution of Candida Species and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV)-Seropositive and At-Risk HIV-Seronegative Women.

The Journal of infectious diseases·2000

Same author

A Versatile Periodate-Coupled Fluorogenic Assay for Hydrolytic Enzymes We would like to thank Prof. R. Furstoss and Dr. A. Archelas at the Faculté des Sciences de Luminy, Marseille (France) for providing a sample of Aspergillus niger EH and Dr. C. Weijers at the Department of Food Technology and Nutrition Sciences, Wageningen University (the Netherlands) for providing a sample of Rhodotorula glutinis EH. This work was supported by the University of Bern, the European COST program (Action D12), the Swiss Office Fédéral de l'Education et de la Science, the Wander Stiftung, the Ministero della Università e della Ricerca Scientifica e Tecnologica (MURST), and Consiglio Nazionale delle Ricerche (CNR) (Roma). P.C. gratefully acknowledges Merck for generous financial support from the 1999 ADP Chemistry Award.

Angewandte Chemie (International ed. in English)·2000

Area of Science:

Cardiology
Electrophysiology
Heart Failure Management

Background:

Cardiac arrhythmias, including atrial and ventricular types, are prevalent in heart failure patients.
The efficacy and risks of antiarrhythmic treatments in heart failure remain under investigation.
Certain antiarrhythmic drugs, like Class I agents, are contraindicated in heart failure patients.

Purpose of the Study:

To review the current understanding of antiarrhythmic therapies in heart failure.
To evaluate the role of beta-blockers, amiodarone, and implantable cardioverter-defibrillators (ICDs) in managing arrhythmias in heart failure.
To identify patient subgroups who most benefit from specific interventions.

Main Methods:

Review of existing clinical trial data, including CIDS, AVID, MUSTT, and MADIT.

Related Experiment Videos

Analysis of the impact of antiarrhythmic drugs and ICDs on morbidity and mortality in heart failure.

Identification of prognostic factors for ICD therapy effectiveness.

Main Results:

Beta-blockers reduce morbidity and mortality in moderate to severe heart failure.
Amiodarone may benefit patients with advanced heart failure and high heart rates, and can manage atrial fibrillation.
ICDs significantly reduce sudden cardiac death, particularly in patients with severely depressed ejection fraction (<30%) and poor functional class.

Conclusions:

Antiarrhythmic therapy choices in heart failure require careful consideration of risks and benefits.
Beta-blockers and amiodarone have established roles in managing heart failure arrhythmias.
ICDs are crucial for preventing sudden cardiac death in the sickest heart failure patients, with ongoing research into their impact on overall survival.